Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | SLC9A3 | P48764 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPOR | P19235 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25344641 | 0.96 | TSHR (0.47) | TSHRSLC9A3L3MBTL1EPHX2GLP1R | |
| SCHEMBL24840970 | 0.91 | L3MBTL1 (0.38) | TSHRSLC9A3L3MBTL1 | |
| SCHEMBL21291226 | 0.88 | L3MBTL1 (0.44) | TSHRSLC9A3L3MBTL1ALDH1A1TAAR1 | |
| SCHEMBL21290595 | 0.88 | GAA (0.36) | TSHRSLC9A3L3MBTL1 | |
| SCHEMBL24588486 | 0.88 | L3MBTL1 (0.45) | TSHRSLC9A3L3MBTL1GLP1R | |
| SCHEMBL21290649 | 0.87 | L3MBTL1 (0.43) | TSHRSLC9A3L3MBTL1GLP1R | |
| SCHEMBL24759076 | 0.87 | TSHR (0.36) | TSHRSLC9A3L3MBTL1ALDH1A1TAAR1 | |
| SCHEMBL25344800 | 0.86 | TSHR (0.40) | TSHRL3MBTL1ALDH1A1TAAR1SMN1; SMN2 | |
| SCHEMBL24759892 | 0.86 | TSHR (0.43) | TSHRSLC9A3L3MBTL1LMNAALDH1A1 | |
| SCHEMBL24759042 | 0.85 | L3MBTL1 (0.41) | TSHRSLC9A3L3MBTL1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151991-A1 | RNAI AGENTS FOR INHIBITING INFLUENZA A VIRAL GENE EXPRESSION, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023183814-A2 | SUBCUTANEOUS DELIVERY OF RNAI AGENTS FOR INHIBITING EXPRESSION OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) | Arrowhead Pharmaceuticals, Inc. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230265437-A1 | RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023150622-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF CORONAVIRUS (COV) VIRAL GENOMES, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023070082-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF MATRIX METALLOPROTEINASE 7(MMP7), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230013022-A1 | RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-01-19 | — | — | US | disclosed |
| US-20230002767-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-01-05 | — | — | US | disclosed |
| US-20220402947-A1 | Trialkyne Linking Agents and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-12-22 | — | — | US | disclosed |
| US-20220396791-A1 | RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-12-15 | — | — | US | disclosed |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| WO-2021086995-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF BETA-ENAC, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2019161213-A1 | TRIALKYNE LINKING AGENTS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402947-A1 | Trialkyne Linking Agents and Methods of Use | DCLRE1A, DTYMK, RTCB | TSHR 3215/4885SLC9A3 4764/4885L3MBTL1 570/4885 |
| US-20230265437-A1 | RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use | MMP7, MMP1, MMP17 | TSHR 4452/4885SLC9A3 2795/4885L3MBTL1 1021/4885 |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | TSHR 2704/4885SLC9A3 822/4885L3MBTL1 2349/4885 |
| US-20220396791-A1 | RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use | AGER, ASGR1, TLR3 | TSHR 2485/4885SLC9A3 4398/4885L3MBTL1 1906/4885 |
| US-20230013022-A1 | RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use | SCNN1B, SCNN1A, SCNN1G | TSHR 3996/4885SLC9A3 68/4885L3MBTL1 1124/4885 |
| US-20230002767-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | MUC1, ALG1, RNASE1 | TSHR 3694/4885SLC9A3 2262/4885L3MBTL1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.